RxDoctor Payments DataLook up a doctor →

Ava Shamban, MD

Dermatology · Santa Monica, CANPI 1003922162

Payments from drug & device makers

$1,475,033in general payments, 2019–2025

Across 635 payments — averaging $2322.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.2M
  • Merz North America, Inc.$129K
  • Galderma Laboratories, L.p.$122K
  • Revance Therapeutics, Inc.$19K
  • Dermira, Inc.$10K
  • Solta Medical, A Division Of Bausch Health US, LLC$3K
  • plus $9K from 27 others
$109,453in research payments, 2019–2025

Across 20 payments — averaging $5472.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merz North America, Inc.$94K
  • AbbVie$16K

What the payments were for

  • Consulting fees$122,57460%
  • Speaking & faculty fees$11,7576%
  • Travel & lodging$36,72118%
  • Food & beverage$33,19116%
  • Education$2390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,475,033 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$192,558
Medicare patients
222
Services billed
2,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide14$17,285
Clobetasol Propionate12$562
ValacyclovirValacyclovir Hcl25$422
Ketoconazole25$383
Triamcinolone Acetonide23$201
Mupirocin14$91

Paid to pharmacies, not to this prescriber.

Other dermatology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →